Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
The Column Group
BioCentury | Nov 7, 2024
Management Tracks
Celltex names Anita Perry CEO
Plus: Arnav Mehta joins The Column Group as venture partner and an update from Acumen
BioCentury | Oct 22, 2024
Product Development
Newco trend watch: Clusters of launches point to areas undergoing derisking
Oligo delivery to the kidney, and two emerging use cases for T cell engagers, each get newcos; most with mega-
BioCentury | Oct 8, 2024
Emerging Company Profile
Judo Bio: Making the kidney the access point for siRNA therapies
New Cambridge, Mass., biotech is delivering oligonucleotides to the kidneys to treat systemic and renal diseases
BioCentury | Sep 19, 2024
Finance
Series A cash for Brenus, GCTx, Nura among week’s VC highlights
Also in BioCentury’s latest Venture Report: New investment initiatives from Novo and RA Capital
BioCentury | Sep 18, 2024
Management Tracks
New CEOs at Nura, IMU
Plus: Structure strengthens team and updates from RegenxBio, Mirador, Abata, Entact, Nautilus and more
BioCentury | Sep 5, 2024
Discovery & Translation
AI for target discovery: the start of a long road
Back to School 2024: Investments in AI in drug discovery pick up, as the picture starts to form of how target discovery may benefit
BioCentury | Aug 9, 2024
Finance
Venture Report: Pair of crossover rounds for precision oncology, peptide biotechs
Plus: Financings for newcos Nilo, Jade, Red Queen
BioCentury | Jul 18, 2024
Finance
Venture Report: Five biotechs raise nearly $800M in two-day flurry
Plus: New capital for CytoReason, Truvian and Renalys
BioCentury | Jun 14, 2024
Finance
Venture Report: Clinical plays Alzheon, Bright Peak raise growth capital
Plus: Early-stage financings for InduPro, Syntis and Moleculent; J.P. Morgan closes its life sciences vehicle; and a new fund for spinal injury
BioCentury | Apr 23, 2024
Deals
Incyte’s hopes for mast cell program spur $750M Escient takeout
Deal gives Incyte clinical molecules for inflammatory, dermatological disorders
Items per page:
1 - 10 of 258